Upadacitinib (Rinvoq®). HTA ID: 19047

Assessment Status Rapid review complete
HTA ID 19047
Drug Upadacitinib
Brand Rinvoq®
Indication For the treatment of moderate-to-severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs. Upadacitinib may be used as monotherapy or in combination with methotrexate.
Assessment Process
Rapid review commissioned 21/10/2019
Rapid review completed 10/12/2019
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of upadacitinib (Rinvoq®) compared with the current standard of care, on the basis of the proposed price relative to currently available therapies.

The HSE has approved reimbursement following confidential price negotiations February 2021.